Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d three years and older are planned to enroll in the trial, which is targeted to be conducted in 10 to 15 sites across the US, Europe and Canada. The study will comprise ABH001 applications sufficient to cover the surface area of the wound, applied topically every 4 weeks with protocol-specified dressings until healed or for up to 24 weeks.

"We are excited that Shire Regenerative Medicine has launched this trial," said Brett Kopelan , Executive Director of the Dystrophic EB Research Association of America (DebRA ) and father to a 5-year-old girl with recessive dystrophic EB.  "While there is currently no cure for EB, I am encouraged that ABH001 is…targeting the chronic wounds that are the hallmark of this disease. I applaud Shire for pushing this forward and look forward to working closely with them as the trial progresses."  

"We are very eager to begin evaluating ABH001 as a potential wound treatment option for people with EB. We believe it has the potential to initiate and continue wound healing in this patient population," said Jeff Jonas , MD, President of Shire Regenerative Medicine. "We are committed to developing regenerative medicine solutions that enable people with life-altering conditions to lead better lives, and are encouraged by the fast track and orphan drug designations we have received to further develop this potential therapy for people, most often young children, suffering from this devastating condition."

Shire is also developing an intravenous protein replacement therapy for the treatment of dystrophic EB, which the company's Human Genetic Therapies business recently acquired from Lotus Tissue Repair, Inc. Initiation of this pivotal trial of ABH001 for patients with EB further demonstrates Shire's commitment to developing a portfolio of products targeted toward patients who suffer from this di
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... multi-product healthcare company catering to the mother and child segment, today ... across the PRC, Singapore , Hong ... , the Philippines and ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 With the ability ... HD resolution for more than 15 minutes, Fastec Imaging has ... world of high speed imaging. “Finally, a high speed camera ... we use in our everyday lives.” proclaims Matt Kearney, VP ... has always been to demystify and simplify the traditionally complicated ...
(Date:7/23/2014)... N.J. (PRWEB) July 23, 2014 ... Comprehensive Cancer Center has joined its Strategic Alliance ... Strategic Alliance Partnership program, UNC Lineberger will have ... to raise awareness of its cutting-edge research initiatives, ... from UNC Lineberger will work with OncLive to ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 a2z Inc. ... ChirpE Mobile App, AACC Pathfinder, in its 2014 ... AACC’s annual meeting is planned for July 29-31, 2014 ... place to be to connect with global leaders in ... management, and other areas of breaking science in laboratory ...
Breaking Biology Technology:China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... Calif., May 28 CV Therapeutics,Inc. (Nasdaq: ... Nasdaq,marketplace rule 4350, the Company issued new inducement ... hiring, primarily in connection,with its commercialization efforts in ... cover an aggregate 151,800 shares of,common stock and ...
... with research institute to aid in successful mid-career changes, ... Center,( http://www.biocareercenter.com ) an online job board and careers ... Research,Institute who has developed Career Navigator -- a new ... within their fields with success --,to launch this new ...
... SoluLinK, Inc., a leader in,next-generation conjugation products ... of a new product, NanoLink(TM) Streptavidin Magnetic,Microspheres. ... of any commercially available polymer-encapsulated streptavidin,magnetic microsphere. ... throughput robotic applications where high biotin loads,must ...
Cached Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2Online Career Service Turns Focus to 'Switching Gears' 2SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2
(Date:7/23/2014)... essential fatty acids and energy to infants and ... concern that soybean-based emulsions could compromise immune functions ... Combination lipid emulsions based on triglyceride oil, fish ... address this concern. , However, researchers at Rutgers ... unwarranted, according to a review published today in ...
(Date:7/22/2014)... The exhibit consists of both still images and ... of scientific research. Forty-four still images were chosen ... students, postdocs, staff, and alumni representing more than ... from more than 50 submissions. , Zach Donnell, ... of the 2014 organizers, noted that the exhibit ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2014. ... million, an increase of 53% compared to $4.4 million in ... income in the second quarter of 2014 was $1.4 million ... The increase in revenue and operating income was driven by ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... (NASDAQ: ABPI) announces evidence that most, if not all ... fungal-induced inflammation as originally proposed by investigators at the ... of the Companys ongoing pivotal Phase 3 clinical trial ... of the antifungal amphotericin B 0.01% suspension. In ...
... most renowned physicists and engineers, OSA,s Frontiers in Optics meeting ... developments in the science of light. What: Frontiers ... 16-20, 2007 Where: Fairmont Hotel, San Jose, Calif. ... A new device that may help give sight to the ...
... great flood of Noahs generation really occur thousands of years ... ancient tsunami" Will pollution levels in our deep seas remain ... of the questions that are being addressed by a new ... non-profit research and education organization, EcoOcean. The team, ...
Cached Biology News:SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma 2Frontiers in Optics presents scientific advancements 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 3
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... A simultaneous dual parameter assay ... poly caspase activity. Active caspases are ... peptide inhibitors, which are cell-permeable, non-cytotoxic ... caspases within the cells. At the ...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: